ArticleJournal of physical therapy science2025
Presence of transthyretin amyloidosis cardiomyopathy influences the prognosis of patients with acute decompensated heart failure undergoing cardiac rehabilitation.
Article in Journal of physical therapy science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[Purpose] This study aimed to investigate the changes in physical function during hospitalization and their impact on the outcomes of patients with transthyretin amyloidosis cardiomyopathy who experienced acute decompensated heart failure and underwent acute cardiac rehabilitation. [Participants and Methods] A matched cohort of 18 and 54 patients with and without transthyretin amyloidosis cardiomyopathy, respectively, was created and analyzed. [Results] Compared to patients without transthyretin amyloidosis cardiomyopathy, those with transthyretin amyloidosis showed similar improvements in grip strength, quadriceps isometric strength, short physical performance battery, and usual gait speed during hospitalization. However, transthyretin amyloidosis cardiomyopathy was associated with a significantly increased risk of both rehospitalization due to heart failure and all-cause mortality. [Conclusion] Although the extent of changes in physical function during hospitalization was similar in patients with and without transthyretin amyloidosis cardiomyopathy, transthyretin amyloidosis cardiomyopathy was associated with poorer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.